11. CSTC-Loop and Sensorimotor Gating
Parietal cortex Prim.-sensori.
Temporal cortex Cortex
Hippocampus
C. m.
-Glu
Frontal
Cortex
Striatum Pallidum Extro-
Thalamus
ceptive
& intro-
-DA +DA ceptive
VTA
Stimuli
+5-HT +5-HT +5-HT
RA
12. D2-Besetzung durch Neuroleptika und
klinische Wirksamkeit I
Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S (2007)
Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a
double-blind PET study in schizophrenia. Neuropsychopharmacology 32: 1209-15
15. Figure 2. Mean Standardized Improvement as a Function of Initial Severity and Treatment
Group.
Drug improvement is portrayed as red triangles around their solid red regression line and placebo
improvement as blue circles around their dashed blue regression line; the green shaded area indicates
the point at which comparisons of drug versus placebo reach the NICE clinical
significance criterion of d ¼ 0.50. Plotted values are sized according to their weight in analyses.
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, et al., PLoS Medicine Vol. 5, No. 2, e45 doi:10.1371/journal.pmed.0050045
16. Figure 3. Mean Standardized Improvement as a Function of Initial Severity and Treatment
Group, Including Only Trials Whose Samples Had High Initial Severity
Drug improvement is portrayed as red triangles around their solid red regression line and placebo
improvement as blue circles around their dashed blue regression line; the green shaded area
indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance
criterion of d ¼ 0.50. Plotted values are sized according to their weight in analyses.
doi:10.1371/journal.pmed.0050045.g003